Treatment of pyoderma gangrenosum with topical factor XIII

Eur J Dermatol. 2013 Sep-Oct;23(5):653-7. doi: 10.1684/ejd.2013.2147.

Abstract

Pyoderma gangrenosum (PG) is a severe ulcerative skin disease. Despite systemic immunosuppressive therapy, PG ulcers often progress and can develop into life-threatening conditions. In this case series, we treated 6 patients suffering from recalcitrant PG with topical coagulation factor XIII, which has been shown to exert beneficial effects on tissue regeneration and wound healing. All 6 patients showed a positive response to treatment with a marked reduction in wound size that was maintained during a 3-month follow-up period. The treatment was well tolerated with no remarkable adverse effects or complications. Topical factor XIII has potential in combination with standard immunosuppressive therapy for the treatment of PG.

Keywords: factor FXIII; pyoderma gangrenosum; therapy.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Anti-Inflammatory Agents / therapeutic use
  • Coagulants / administration & dosage*
  • Drug Therapy, Combination
  • Factor XIII / administration & dosage*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prednisolone / therapeutic use
  • Pyoderma Gangrenosum / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Coagulants
  • Factor XIII
  • Prednisolone